Hypopigmentation from imatinib mesylate (Gleevec).
Grossman
William J
WJ
St. Louis Children's Hospital, Hale Irwin Center for Hematology and Oncology, Washington University School of Medicine, 660 S. Euclid Ave., St. Louis, MO 63110, USA. grossman_w@kids.wustl.edu
Wilson
David B
DB
D000970:Antineoplastic Agents / Q000009:adverse effects*; D001549:Benzamides; D044383:Black People; D002648:Child; D036101:Cord Blood Stem Cell Transplantation; D006801:Humans; D017496:Hypopigmentation / Q000139:chemically induced*; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000628:therapy; D008297:Male; D008923:Missouri; D010879:Piperazines / Q000009:adverse effects*; D011743:Pyrimidines / Q000009:adverse effects*; D001741:Black or African American
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate